<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023239</url>
  </required_header>
  <id_info>
    <org_study_id>n-2021</org_study_id>
    <nct_id>NCT05023239</nct_id>
  </id_info>
  <brief_title>Ultrasound-Guided Suprazygomatic Maxillary Nerve Block as A Part of Multimodal Analgesic Regimens</brief_title>
  <official_title>The Effect of Ultrasound-Guided Suprazygomatic Maxillary Nerve Block for Minimize the Post-operative Pain in Tonsillectomy Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inadequate peri-operative analgesia may contribute to an increased risk of bleeding, suture&#xD;
      dehiscence and unacceptable surgical outcomes. Moreover, these patients are at high risk of&#xD;
      postoperative airway obstruction and respiratory failure.&#xD;
&#xD;
      Opioids may contribute to these complications. Appropriate use of regional anaesthesia may&#xD;
      mitigate or eliminate many of these concerns. The maxillary nerve is responsible for the&#xD;
      sensory innervation of the midface, including the hard and soft palates, upper jaw, upper&#xD;
      dental arch and upper lip.Recently, the successful use of maxillary nerve block by the&#xD;
      suprazygomatic approach has been reported in children undergoing cleft palate surgery.&#xD;
      However, the use of this block has not been described in large series of patients, and the&#xD;
      effectiveness of the suprazygomatic approach has not been evaluated in patients undergoing&#xD;
      tonsillectomy .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative Meperidine consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>total dose of Meperidine consumption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of complication</measure>
    <time_frame>24 hours</time_frame>
    <description>postoperative complication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Suprazygomatic Maxillary Nerve Block</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>patients will receive sham block by 10 ml of normal saline (5 mL in each side) as a control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UG-SZM Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will be receive bilateral Ultrasound-Guided Suprazygomatic Maxillary (UG-SZM) Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>UG-SZM Group</intervention_name>
    <description>The patients will be receive Ultrasound-Guided Suprazygomatic Maxillary Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine .</description>
    <arm_group_label>UG-SZM Group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria&#xD;
&#xD;
               1. Pediatric patients aged 4-12 years&#xD;
&#xD;
               2. Genders eligible for study: both sexes&#xD;
&#xD;
               3. ASA physical status I and II&#xD;
&#xD;
               4. Undergoing tonsillectomy surgery&#xD;
&#xD;
                  Exclusion criteria&#xD;
&#xD;
          -  Parents' refusal&#xD;
&#xD;
          -  Contraindications to regional anesthesia&#xD;
&#xD;
          -  Known allergy to local anesthetics&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Children with diabetes mellitus, obstructive sleep apnea syndrome, cardiac, renal,&#xD;
             liver or blood diseases, swallowing disorders or peritonsillar abscess,&#xD;
&#xD;
          -  Children receiving regular analgesia within the last week before surgery,&#xD;
&#xD;
          -  Children undergoing simultaneous procedure in the field of surgery like adenoidectomy&#xD;
             or tongue tie will be all excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>amr wahdan, MD</last_name>
    <phone>01001422499</phone>
    <email>amr_amw010@hotmail.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 21, 2021</last_update_submitted>
  <last_update_submitted_qc>August 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Amr Samir Wahdan</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia, Pain management and Surgical ICU</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

